| Bravo Health, Inc. |
| Bravo Health, Inc. is a Medicare health plan that targets members eligible for both Medicare and Medicaid. The population the firm focuses on serving has, on average, five or more chronic illnesses. Bravo Health typically serves Medicare populations in urban areas and coordinates care through one primary physician who can help improve patient care through active disease management while lowering medical costs incurred by the company.1, 2 |
| |
| Cardica, Inc. (CRDC) |
| Cardica designs and manufactures proprietary automated anastomotic systems used by surgeons to perform coronary artery bypass graft (CABG) surgery. In CABG procedures, veins or arteries are used to construct alternative conduits to restore blood flow beyond narrowed or occluded portions of coronary arteries, "bypassing" the narrowed or occluded portion of the artery that is impairing blood flow to the heart muscle.1 |
| |
| CyroCor, Inc. (Acquired) |
| CryoCor, Inc. is a medical technology company headquartered in San Diego, California developing products that use cryogenic technology to treat cardiac rhythm disorders called arrhythmias. Cardiac cryoablation is a non-surgical, minimally-invasive procedure in which a cardiologist inserts a catheter into a blood vessel in the leg of an afflicted individual and advances it into the heart.1 |
| |
| Data Sciences International, DSI |
| Data Sciences International, Inc. is a provider of wireless implantable devices for monitoring and collecting physiological data.1, 2 |
| |
| GeneOhm Sciences, Inc. (Acquired) |
GeneOhm Sciences, Inc. is a molecular diagnostic company. GeneOhm’s product portfolio includes two assays cleared by the FDA and Health Canada for rapid detection directly from clinical specimens of Group B Streptococcus (IDI-Strep BTM) and Methicillin-Resistant Staphylococcus aureus (IDI-MRSATM). IDI-MRSATM is also CE-marked and available for European sale. These molecular diagnostic products are the first to be cleared as meeting the specifications required to replace culture for microorganism detection.
Acquisition by Becton, Dickinson and Company on February 13, 20062 |
| |
| MedManage Systems (Acquired) |
MedManage Systems provides the industry's most comprehensive prescription drug sampling solutions. Representing a major advance in the marketing of prescription medications, the company's OmniSample Solution allows pharmaceutical companies to apply a proven marketing strategy -- the use of sample medications to influence physician prescribing behavior -- to achieve broader, deeper and faster market penetration and provide a comprehensive sampling system through all stages of the product life cycle.
Acquisition by Physicians Interactive on April 1, 20091 |
| |
| Neurogesx (NGSX) |
| NeurogesX is a biopharmaceutical company focused on developing and commercializing novel pain management therapies to relieve chronic pain and improve quality of life. The company is assembling a portfolio of pain management product candidates and is developing innovative new therapies based on known chemical entities. 1 |
| |
| NxStage Medical, Inc. (NXTM) |
NxStage Medical, Inc. is a medical device company that has tapped a potentially very large market by developing a hemodialysis machine for in-home use. Currently the device is being marketed for use in the intensive care units of hospitals and for in-home use. The company believes its hemodialysis machine is compact and easy to use, and in contrast with systems used in dialysis centers today, does not require complicated electrical and plumbing connections to be made to the home.
NxStage completed its initial public offering in October 2005.1, 2 |
| |
| Ocera Theraputics |
| Ocera Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the licensing, development and commercialization of proprietary compounds to treat a broad range of gastrointestinal and liver diseases. Ocera’s goal is to develop safe and novel therapies that address significant unmet medical needs in the treatment of Inflammatory Bowel Diseases.1 |
| |
| OREXIGEN Therapeutics, Inc. (OREX) |
OREXIGEN™ is developing a novel strategic approach to the treatment of obesity. OREXIGEN develops and screens rational drug combinations based on the company's proprietary understanding of how the brain controls feeding. OREXIGEN'S goal is to develop and commercialize new, proprietary combinations of currently available drugs that are designed to achieve and sustain weight loss by enhancing satiety, diminishing appetite, improving energy expenditure and minimizing the body's efforts to compensate for weight loss.
Orexigen completed its initial public offering in May 2007.1 |
| |
| Rules-Based Medicine, Inc. |
| Rules-Based Medicine (RBM) is a leading multiplexed biomarker testing company providing comprehensive protein biomarker products and services based on its Multi-Analyte Profiling (MAP) technology platform. RBM’s biomarker testing service provides pre-clinical and clinical researchers with reproducible, quantitative, multiplexed immunoassay data for hundreds of proteins in a cost-effective manner, from a small sample volume and from multiple species.1 |
| |
| TherOx, Inc. |
| TherOx, Inc. is a medical device company focused on the treatment of patients after they suffer heart attacks by mixing oxygen with a patient's blood and delivering the mixture to oxygen-deprived muscles via a catheter.2 |
| |
| Vapotherm, Inc. |
| Vapotherm, Inc. is a leading developer of respiratory airway therapies that provide non-invasive, comfortable high-flow oxygen therapy to patients with chronic or acute breathing disorders. The company’s Precision Flow™ device synchronizes flow, temperature, humidity and oxygen percentage without nasal discomfort.1 |
| |
| 1 |
|
Investment made by Cross Creek Capital, L.P. |
|
| 2 |
|
Investment made by one or more members of the Cross Creek Capital team on behalf of Wasatch's clients since January 1, 2004. This investment was made prior to the formation of Cross Creek Capital. |
|